Actively Recruiting
Evaluating Safety, Immune Response, and Optimal Dose of MOPEVAC-Las Vaccine Candidate for Lassa Fever in Healthy Adults
Led by Institut Pasteur · Updated on 2026-10-13
72
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Lassa fever is a serious viral disease common in West Africa, causing significant illness and death each year. Researchers are conducting a phase 1 clinical trial to evaluate the safety, immune response, and best dose of a new vaccine candidate called MOPEVAC-Las for healthy adult volunteers. This study compares the vaccine to a placebo to understand its effects and tolerability. Participants will be divided into three groups receiving low, intermediate, or high doses of the MOPEVAC-Las vaccine, with an additional placebo group in each. Each participant will receive two injections, given on day 0 and day 60. The study includes a total of 11 visits over 14 months, covering screening, vaccination, and follow-up assessments. Throughout the study, participants will undergo monitoring for side effects and immune responses through blood tests and other evaluations. Researchers will measure adverse events up to 28 days after each injection and assess immune cells and antibody levels at multiple time points, including up to one year after the second dose. Safety and tolerability will be closely followed to determine the vaccines optimal dose and potential for further development.
CONDITIONS
Brief Title
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Research Team
S
Sandrine Fernandes Pellerin
M
Maëlys Petit-Moreau
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here